Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.
Transforming the lives of those suffering from vision loss
A revolutionary eye drop
Eye drops to treat diseases such as wet AMD and DME which will not onlyoffer improved quality of life for patients
| Status | Active |
| Website | https://www.exonate.com/ |
| Category | Biotech |
| Modality | Small Molecule |
| Therapautics Area | Ocular |
| Headquaters | Cambridge, UK |
| Partner | Johnson and Johnson |
| Investment Portfolio | Fund Investment |
| Co-Investors | The University Of Nottingham Parkwalk, Angel Cofund, Wren Capital University of Bristol Enterprise Fund |